Guardant Health Inc.

**RTW Investments Signal Note: Guardant Health (GH)** Roderick Wong's $151.3M initiation in Guardant suggests conviction in GH's liquid biopsy expansion beyond oncology monitoring, likely driven by near-term catalysts in early detection (Shield study readouts expected 2024-2025) or clinical validation in emerging indications. The position size and new entry timing may reflect confidence in margin expansion as ctDNA testing achieves reimbursement parity and volume scaling in routine care pathways. Key catalysts: Medicaid/Medicare coverage decisions and USPSTF guidance updates on blood-based cancer screening.